NTIDC - North Texas Infectious Disease Consultants

07/08/2026

Weight gain during HIV treatment is a very real concern for many patients, and a massive new North American study reveals just how nuanced the topic truly is. While certain modern regimens show higher average weight trajectories, every individual's body reacts differently.

At NTIDC, we validate these concerns and prioritize long-term, comprehensive metabolic health. Effective HIV therapy is never "one size fits all." It’s about finding the right balance of efficacy, tolerability, and personal well-being for you.

Read the latest findings here: https://www.thebodypro.com/hiv/weight-gain-antiretrovirals-insti-july-2026

The latest major study exploring the role of antiretrovirals in weight gain has arrived—and its findings don’t fit neatly into either side of the debate.

07/04/2026

Happy 4th of July!
Wishing you and your loved ones a safe, joyful, and memorable Independence Day.

06/21/2026

Happy Father’s Day! Thank you to all the wonderful fathers!

06/16/2026

Could the future of HIV care mean living untethered from a daily pill?

A newly published study in The Lancet HIV—the RIO trial—is bringing broadly neutralizing antibodies (bNAbs) back into the spotlight. The study showed that a combination of two long-acting antibodies successfully delayed viral rebound in 75% of participants who paused their antiretroviral therapy (ART) for 20 weeks.

While this won't change everyday clinical care immediately, it provides incredibly exciting "proof of concept" data for immune-based, long-acting HIV remission strategies down the road.

Read the full expert breakdown from TheBodyPro 👇
https://www.thebodypro.com/hiv/broadly-neutralizing-antibodies-rio-study-20-weeks-lancet-hiv-june-2026

The RIO study demonstrates long-acting broadly neutralizing antibodies can delay HIV rebound after stopping antiretroviral therapy, offering hope for new treatment strategies.

06/15/2026

The World Cup is here! As millions of fans gather in stadiums, bars, and airports, infectious disease experts are highlighting the unique health risks associated with a six-week mass gathering.

Measles, respiratory viruses, and food-borne illnesses top the list of concerns. The good news? Staying up-to-date on vaccinations and practicing strict hand hygiene are highly effective ways to keep yourself safe while enjoying the games.

Read more from TODAY Health: https://www.today.com/health/news/2026-fifa-world-cup-outbreak-risks-infections-diseases-doctors-explain-rcna349202

From measles to norovirus, here’s which infectious diseases could spread during the 2026 World Cup and how to protect yourself.

05/25/2026

This Memorial Day, we remember and honor those who gave their lives in service to our nation.

05/10/2026

Happy Mother’s Day!

04/30/2026

You may have seen "Cicada" trending online — and no, it's not about the insects. 🦗

The CDC and WHO are both monitoring a COVID-19 variant called BA.3.2, nicknamed "Cicada," which has been detected in at least 25 U.S. states and 23 countries. While it's spreading, it is not yet the dominant strain in the U.S., and the CDC is not currently reporting a nationwide increase in severe disease, hospitalizations, or emergency visits.

That said, experts note the variant may have some ability to partially evade existing immunity. The CDC recommends staying up to date on your COVID vaccine, especially if you are 65 or older, immunocompromised, or have chronic health conditions like heart or lung disease.

As always, if you have questions or concerns, our team is here. Stay informed, stay protected. 🛡️
https://www.cbsnews.com/news/covid-19-variant-cicada-ba32/

The COVID-19 variant BA.3.2, nicknamed "Cicada," has been detected in at least 23 countries and half the states in the U.S.

04/29/2026

HIV prevention is becoming more convenient than ever. At CROI 2026, researchers shared major updates on two longer-acting PrEP options now in Phase III trials:

💉 Once-Yearly Lenacapavir (Injectable) — Building on the already groundbreaking twice-yearly Yeztugo shots (which were 100% effective in women and 96% effective in gay and bisexual men in trials), Gilead is now pushing toward a once-yearly intramuscular injection. The Phase III PURPOSE 365 trial is actively recruiting diverse participants ages 16 and up who are at risk for HIV.

💊 Once-Monthly Oral PrEP (MK-8527) — For people who prefer a pill, Merck's MK-8527 showed strong safety and protective drug levels throughout an entire month — with a forgiving 7-day dosing window. Two large Phase III trials are now underway across 16+ countries.

Fewer doses. Same powerful protection. More options mean more people can find something that works for their lifestyle.

Have questions about PrEP? Our team is here to help you find the right fit. 💬
https://www.poz.com/article/next-steps-longeracting-prep

Once-yearly injectable PrEP and once-monthly prevention pills are now in late-stage trials.

04/28/2026

A new treatment option is here for people living with HIV. The FDA has approved Idvynso — a once-daily, single-tablet regimen combining doravirine and islatravir — as a switch option for adults with an undetectable viral load.

What makes this notable? It's the first complete HIV regimen without an integrase inhibitor or tenofovir, offering a genuinely new class of treatment. Studies also showed stable kidney function biomarkers and minimal changes in weight, lipid levels, and blood sugar compared to existing options.

If you're currently on HIV treatment and wonder if Idvynso might be right for you, talk to your provider. Our team is here to help. 💊
https://www.poz.com/article/fda-approves-new-hiv-combo-pill-idvynso

Once-daily doravirine/islatravir single-tablet regimen is a switch option for people with viral suppression.